Shilpa Medicare has received Drugs Controller General of India (DCGI) approval for ‘2-Deoxy2-Glucose’ (Bulk & Oral Powder). The bulk is manufactured by Shilpa Medicare, API facility in Raichur,' Karnataka. The Oral Powder is manufactured by its subsidiary, Shilpa Therapeutics, facility in Hyderabad, Telangana. 2-Deoxy-2-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients. The product will be available with a brand name '2-DGSHIL'.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1525.00 |
Dr. Reddys Lab | 5942.65 |
Cipla | 1345.35 |
Zydus Lifesciences | 925.95 |
Lupin | 1547.05 |
View more.. |